BIOMAT Database Logo BIOMAT Database Logo

Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. 1992

J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Ottawa Regional Cancer Center, Ontario, Canada.

Forty-three patients received etoposide, cyclophosphamide, and fractionated total body irradiation before allogeneic marrow transplantation. Fifteen patients had chronic myelogenous leukemia in chronic phase or acute leukemia in first remission (standard risk) and twenty-eight patients with more advanced disease (high risk). All patients received etoposide 1,500 mg/m2 intravenously on day -8, cyclophosphamide 60 mg/kg/day intravenously on days -7 and -6, and total body irradiation at 170 cGy twice a day on days -3, -2, and -1. During the first 100 days 12 high risk patients (43%) died from causes unrelated to relapse while none of the standard risk patients died. Renal and hepatic dysfunction were also significantly increased during the first 14 days in the high risk group. The addition of 1,500 mg/m2 of etoposide to the cyclophosphamide and total body irradiation was well tolerated for patients with standard risk. However, the regimen was poorly tolerated with high mortality in patients with more advanced disease.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females

Related Publications

J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
September 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
December 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
October 2004, Clinical transplantation,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
March 2000, Bone marrow transplantation,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
July 1992, Bone marrow transplantation,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Allogeneic bone marrow transplantation for plasma cell leukemia following melphalan, cyclophosphamide and total body irradiation.
May 1989, Bone marrow transplantation,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Fractionated total body irradiation and allogeneic bone marrow transplantation for standard risk leukemia.
December 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
September 1989, Bone marrow transplantation,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Growth following single fraction and fractionated total body irradiation for bone marrow transplantation.
November 1993, European journal of pediatrics,
J C Yau, and C F LeMaistre, and B S Andersson, and S D Huan, and R O Wallerstein, and S Y Woo, and G Spitzer, and J A Spinolo, and V Spencer, and L J Brunner
Allogeneic bone marrow transplantation for hematological malignancies following therapy with high doses of busulphan and cyclophosphamide.
January 1989, Haematologica,
Copied contents to your clipboard!